LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Search

Omnicell Inc

Închisă

SectorSănătate

36.29 0.3

Rezumat

Modificarea prețului

24h

Curent

Minim

36.29

Maxim

36.79

Indicatori cheie

By Trading Economics

Venit

-7.5M

-2M

Vânzări

3.4M

314M

P/E

Medie Sector

912.5

121.746

EPS

0.51

Marjă de profit

-0.645

Angajați

3,600

EBITDA

-10M

21M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+59.45% upside

Dividende

By Dow Jones

Următoarele câștiguri

5 mai 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

-560M

1.7B

Deschiderea anterioară

35.99

Închiderea anterioară

36.29

Sentimentul știrilor

By Acuity

40%

60%

87 / 351 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Strong Bearish Evidence

Omnicell Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

15 feb. 2026, 23:21 UTC

Achiziții, Fuziuni, Preluări

Qube Agrees to Takeover by MAM-Led Consortium Valuing Its Equity at $6.51 Billion

15 feb. 2026, 23:45 UTC

Market Talk

Nikkei May Rise as Fears About AI Disruption Recede -- Market Talk

15 feb. 2026, 23:40 UTC

Market Talk

Gold Falls on Possible Position Adjustments -- Market Talk

15 feb. 2026, 23:06 UTC

Câștiguri

Thai Beverage: Spirits, Beer Businesses Posted Satisfactory EBITDA Growth, Alongside Profit Margin Expansion>Y92.SG

15 feb. 2026, 23:04 UTC

Câștiguri

Thai Beverage 1Q Beer Business EBITDA THB4.64B, Up 4.7% on Year>Y92.SG

15 feb. 2026, 23:04 UTC

Câștiguri

Thai Beverage 1Q Spirits Business EBITDA THB8.50B, Up 6.9% on Year >Y92.SG

15 feb. 2026, 23:01 UTC

Câștiguri

Thai Beverage 1Q EBITDA THB16.75B, Up 1.8% on Year >Y92.SG

15 feb. 2026, 23:01 UTC

Câștiguri

Thai Beverage 1Q FY Sales Revenue THB86.70B, Down 6.0% on Year>Y92.SG

15 feb. 2026, 22:53 UTC

Achiziții, Fuziuni, Preluări

Qube: MAM-Led Offer Implies A$11.7 Billion Enterprise Value

15 feb. 2026, 22:53 UTC

Achiziții, Fuziuni, Preluări

Qube: UniSuper to Transfer 15.07% Stake to Equivalent Ownership of Consortium Holding Structure

15 feb. 2026, 22:52 UTC

Achiziții, Fuziuni, Preluări

Qube Shareholders to Receive A$5.20/Share in Cash

15 feb. 2026, 22:52 UTC

Achiziții, Fuziuni, Preluări

Qube Holdings Agrees to Takeover by Macquarie Asset Management-Led Consortium

15 feb. 2026, 22:22 UTC

Achiziții, Fuziuni, Preluări

BlueScope CEO Tania Archibald Speaking on a Call With Media

15 feb. 2026, 22:17 UTC

Achiziții, Fuziuni, Preluări

BlueScope CEO: Stresses Whyalla Project Would Have to Make Sense to Shareholders

15 feb. 2026, 22:16 UTC

Achiziții, Fuziuni, Preluări

BlueScope CEO: Some Job Cuts Inevitable to Ensure Company is Competitive

15 feb. 2026, 22:14 UTC

Achiziții, Fuziuni, Preluări

BlueScope CEO: Higher Returns Tied to End of Capital Investment Program

15 feb. 2026, 22:14 UTC

Achiziții, Fuziuni, Preluări

BlueScope Steel CEO: Higher Returns After Rebuffed Takeover Bid a 'Natural Coincidence'

15 feb. 2026, 20:48 UTC

Câștiguri

BlueScope: Will Now Target Net Debt of Up to A$1.5 Billion; Will Surpass as Needed

15 feb. 2026, 20:47 UTC

Câștiguri

BlueScope: Expects Full Benefits of Further A$150M Cost Savings in FY 2027

15 feb. 2026, 20:46 UTC

Câștiguri

BlueScope: Recorded Net Annualized Cost Improvements of A$190 Million in 1H

15 feb. 2026, 20:45 UTC

Câștiguri

BlueScope Expects a One-Third Lower 2H Result From Asia Business Vs 1H

15 feb. 2026, 20:44 UTC

Câștiguri

BlueScope Expects 15% Higher 2H Result From North America Business Vs 1H

15 feb. 2026, 20:44 UTC

Câștiguri

BlueScope Expects Lower 2H Result From Australia Business Vs 1H

15 feb. 2026, 20:43 UTC

Câștiguri

BlueScope Expects 2H Underlying Ebit of A$620 Million-A$700 Million

15 feb. 2026, 20:42 UTC

Câștiguri

BlueScope Net Debt A$2.2 Million at Dec. 31

15 feb. 2026, 20:42 UTC

Câștiguri

BlueScope 1H Underlying Ebit A$557.5 Million, Up 81% On-Year

15 feb. 2026, 20:41 UTC

Câștiguri

BlueScope 1H Underlying Ebitda A$915.3 Million, Up 39% On-Year

15 feb. 2026, 20:40 UTC

Câștiguri

BlueScope 1H Underlying Profit A$382.0 Million Vs A$176.4 Million Year Prior

15 feb. 2026, 20:40 UTC

Câștiguri

BlueScope 1H Sales Revenue From Continuing Ops A$8.22 Billion, Up 4% On-Year

15 feb. 2026, 20:39 UTC

Câștiguri

BlueScope Intends to Spend A$310 Million on Buyback, Or Other Returns if Share Repurchases Limited

Comparație

Modificare preț

Omnicell Inc Așteptări

Obiectiv de preț

By TipRanks

59.45% sus

Prognoză pe 12 luni

Medie 58.2 USD  59.45%

Maxim 70 USD

Minim 49 USD

În baza a 7 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruOmnicell Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

7 ratings

6

Cumpărare

1

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

24.23 / 30.44Suport & Rezistență

Termen scurt

Strong Bearish Evidence

Termen mediu

Strong Bearish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

87 / 351 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Omnicell Inc

Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots; and inventory management software. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.
help-icon Live chat